| |
| |
|
| Insider
Information: |
Bradbury Daniel |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
223,469 |
|
|
Indirect Shares
|
3,161,475 |
|
|
| Direct
Value |
$2,468,702 |
|
|
|
Indirect Value
|
$3,772,028 |
|
|
| Total
Shares |
3,384,944 |
|
|
| Total
Value |
$6,240,730 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amylin Pharmaceuticals Inc |
AMLN |
President & Chief Exec... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
Paratek Pharmaceuticals Inc |
PRTK |
Director |
2006-05-09 |
35,714 |
|
0 |
Premium* |
|
|
Illumina Inc |
ILMN |
Director |
2017-05-25 |
15,324 |
2008-05-16 |
0 |
Premium* |
|
|
Corcept Therapeutics Inc |
CORT |
Director |
2012-11-21 |
0 |
2019-02-07 |
130,575 |
Premium* |
|
|
Geron Corporation |
GERN |
Director |
2014-05-09 |
142,776 |
2019-03-29 |
51,323 |
Premium* |
|
|
Equillium Inc |
EQ |
Chief Executive Office... |
2018-10-16 |
0 |
2018-10-16 |
2,969,596 |
Premium* |
|
|
Castle Biosciences Inc |
CSTL |
Director |
2024-05-06 |
4,655 |
2024-05-06 |
9,981 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
25,000 |
2021-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
423 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 17
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ILMN |
Illumina Inc |
Director |
– • – |
2009-10-01 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
5,600 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-10-01 |
4 |
AS |
$41.46 |
$150,312 |
D/D |
(3,600) |
4,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-11-05 |
4 |
AS |
$32.76 |
$118,506 |
D/D |
(3,600) |
4,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-11-05 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
5,600 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-11-09 |
5 |
GD |
$0.00 |
$0 |
D/D |
160 |
3,840 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-12-03 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
6,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2009-12-03 |
4 |
AS |
$29.21 |
$105,346 |
D/D |
(3,600) |
4,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-01-06 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
6,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-01-06 |
4 |
AS |
$30.54 |
$113,613 |
D/D |
(3,600) |
4,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-02-03 |
4 |
AS |
$37.48 |
$135,517 |
D/D |
(3,600) |
4,000 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-02-03 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
5,600 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,360 |
4,815 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-03 |
4 |
A |
$17.83 |
$7,346 |
D/D |
412 |
16,524 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
D |
$17.82 |
$625,803 |
I/I |
(35,118) |
44,573 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
OE |
$14.28 |
$636,547 |
I/I |
44,573 |
79,691 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
D |
$17.82 |
$54,048 |
D/D |
(3,033) |
16,524 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
OE |
$14.28 |
$43,314 |
D/D |
3,033 |
19,557 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-26 |
5 |
GD |
$0.00 |
$0 |
I/I |
3,028 |
46,545 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-26 |
5 |
GA |
$0.00 |
$0 |
I/I |
3,028 |
16,185 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,703 |
2,137 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-03-02 |
4 |
OE |
$3.24 |
$16,440 |
D/D |
3,600 |
3,737 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-03-02 |
4 |
AS |
$38.04 |
$137,317 |
D/D |
(3,600) |
2,137 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-03-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
137 |
2,000 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-03-25 |
4 |
OE |
$9.63 |
$48,125 |
I/I |
5,000 |
49,573 |
0 |
- |
|
| ILMN |
Illumina Inc |
Director |
– • – |
2010-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,800 |
3,937 |
0 |
- |
|
423 Records found
|
|
Page 5 of 17 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
